Please enable JavaScript
Powered by Benchmark Saransh Kanaujia, Author at Matribhumi Samachar English - Page 2072 of 2902
Sunday, March 22 2026 | 09:21:42 AM
Home / Saransh Kanaujia (page 2072)

Saransh Kanaujia

Saransh Kanaujia is currently editor of Matribhumi Samachar Group. He earlier worked with Hindusthan Samachar News Agency. He is also associated with many organizations.

Wealth Minerals Acquires the Pabellon Lithium Project

Vancouver, British Columbia–(Newsfile Corp. – February 6, 2025) – Wealth Minerals Ltd. (TSXV: WML) (OTCQB: WMLLF) (SSE: WMLCL) (FSE: EJZN) – (the “Company” or “Wealth”) announces it has executed a non-binding Letter of Intent (the “LOI”) to enter into an option agreement giving it the right to acquire a 100% …

Read More »

Atomic Minerals Corp. Announces Listing on the Frankfurt Stock Exchange Under the Symbol DO80

Vancouver, British Columbia–(Newsfile Corp. – February 6, 2025) – Atomic Minerals Corporation (TSXV: ATOM) (“ATOMIC MINERALS” or the “Company”) is pleased to announce that its shares are now listed for trading on the Frankfurt Stock Exchange (“FSE”) under the symbol “DO80”. This listing will enhance the Company’s visibility and accessibility to …

Read More »

Vortex Metals Provides Exploration and Geophysics Update

Vancouver, British Columbia–(Newsfile Corp. – February 6, 2025) – Vortex Metals Inc. (TSXV: VMS) (FSE: DM8) (OTCQB: VMSSF) (“Vortex” or the “Company”) is pleased to announce that it has completed Phase 1 exploration, with eight holes diamond drill program for a total of 2,025 m, at the Illapel Copper Project …

Read More »

Andean Precious Metals Signs Exclusive Agreement to Purchase up to 250,000 Tonnes of Oxide Material from COMIBOL in Bolivia

Toronto, Ontario–(Newsfile Corp. – February 6, 2025) – Andean Precious Metals Corp. (TSX: APM) (OTCQX: ANPMF) (“Andean”, or the “Company”), through its wholly-owned subsidiary, Empresa Minera Manquiri S.A. (“Manquiri” and together with Andean, the “Andean Entities”) has entered into a Sale and Purchase Agreement (the “SPA” or the “Agreement”) of …

Read More »

NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury

Vancouver, British Columbia–(Newsfile Corp. – February 6, 2025) – NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that the first subject has been enrolled and dosed in the subacute cohort of its Phase 1b/2a proof-of-concept, double-blind, randomized placebo-controlled clinical trial …

Read More »

InFlectis BioScience Announces Promising Results for IFB-088 in a Phase 2a Clinical Study in Bulbar-Onset ALS Patients

Nantes, France–(Newsfile Corp. – February 6, 2025) – InFlectis BioScience SAS, a drug discovery company pioneering development of therapeutics harnessing the Integrated Stress Response (ISR) for a spectrum of neurological diseases, today announced the successful completion of its P288ALS TRIAL study (NCT05508074). This study was designed as a randomized, double-blind, …

Read More »

Plurilock Announces U.S. Federal Contract Extension of NASA SEWP V and Investor Awareness Campaign

SEWP is a government-wide acquisition contract that allows Plurilock to sell IT and cybersecurity products across U.S. federal agencies NASA has extended the SEWP V contract until at least October 31, 2025, ensuring Plurilock’s U.S. subsidiary Aurora remains a trusted cybersecurity provider for U.S. government agencies Vancouver, British Columbia–(Newsfile Corp. …

Read More »